Drug intelligence / Profile preview

G47ΔmADA1

Development stage
Preclinical
Lead developer
Massachusetts General Hospital
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration
Intratumoral
01

Overview

G47ΔmADA1 is an oncolytic herpes simplex virus (oHSV) based on the G47Δ backbone, engineered to express a secreted, codon-optimized mouse adenosine deaminase isoform 1 (mADA1). G47Δ is a third-generation oHSV with deletions in the γ34.5 and ICP47 genes and an inactivation of the ICP6 gene, which enhances its safety and tumor-selective replication. By expressing mADA1, the virus targets the adenosine immunosuppressive pathway in the tumor microenvironment (TME) by converting extracellular adenosine (eADO) into inosine. This reduction in adenosine levels is intended to alleviate immunosuppression and enhance anti-tumor immune responses, particularly in glioblastoma (GBM). Preclinical studies in orthotopic murine glioblastoma models have demonstrated significant therapeutic efficacy and survival benefits compared to the parental G47Δ virus.

Other names
G47delta-mADA1G-47delta-mADA1G 47delta-mADA1mADA1-armed oHSVmADA-1-armed oHSVmADA 1-armed oHSV
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADA (Adenosine deaminase)DPP-4 (Dipeptidyl Peptidase-IV)NECTIN1 (Poliovirus receptor-related 1)

Beyond the preview

Go deeper on G47ΔmADA1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G47ΔmADA1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call